EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cyclophilin inhibition as a strategy for the treatment of human disease

Winston T Stauffer, Asha Z Goodman, Philippe A Gallay

Frontiers in Pharmacology · 08.07.2024 · 15

DOI: 10.3389/fphar.2024.1417945 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.07.2024. Verfasst von Winston T Stauffer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, CA, United States. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclophilins (Cyps), characterized as peptidyl-prolyl cis-trans isomerases (PPIases), are highly conserved and ubiquitous, playing a crucial role in protein folding and cellular signaling. This review summarizes the biochemical pathways mediated by Cyps, including their involvement in pathological states such as viral replication, inflammation, and cancer progression, to underscore the therapeutic potential of Cyp inhibition. The exploration of Cyp inhibitors (CypI) in this review, particularly non-immunosuppressive cyclosporine A (CsA) derivatives, highlights their significance as therapeutic agents. The structural and functional nuances of CsA derivatives are examined, including their efficacy, mechanism of action, and the balance between therapeutic benefits and off-target effects. The landscape of CypI is evaluated to emphasize the clinical need for targeted approaches to exploit the complex biology of Cyps and to propose future directions for research that may enhance the utility of non-immunosuppressive CsA derivatives in treating diseases where Cyps play a key pathological role.

Schlagwörter

Stichwörter der Autor:innen

cyclophilincyclophilin inhibitorshuman diseasehuman diseasestreatmentsviruses

Autor:innen und Institutionen

  • Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, CA, United States.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Stauffer, W. T., Goodman, A. Z., & Gallay, P. A. (2024). Cyclophilin inhibition as a strategy for the treatment of human disease. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1417945

Vancouver

Stauffer WT, Goodman AZ, Gallay PA. Cyclophilin inhibition as a strategy for the treatment of human disease. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1417945

BibTeX
@article{Stauffer2024,
  author = {Stauffer, Winston T and Goodman, Asha Z and Gallay, Philippe A},
  title = {Cyclophilin inhibition as a strategy for the treatment of human disease},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1417945}
}
Kostenlos starten →